3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
7
Colorectal Neoplasms
4
Stomach Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma Of Esophagus
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Meningeal Neoplasms
1
HER2-positive Breast Cancer
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Advanced Unresectable or Metastatic Solid Malignancy
×
tucatinib
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts